This phase I/II trial is using an oral drug (LOXO-101) as a treatment in children and adolescents with central nervous system tumours.
This trial is treating patients with central nervous system tumours.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
LOXO Oncology, Inc
This trial has a single group assignment; all participants will receive oral LOXO-101 (larotrectinib) twice daily, with dose adjusted for body surface area (BSA).
Recruiting Hospitals Read More